Contineum Therapeutics, Inc. Class A (CTNM) AI Stock Analysis

• Market Cap: $540.64M
• Dividend Yield: N/A
• Average Volume (3M): 170.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: N/A
• EPS Growth: -100.71%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 30,446,112
• 10 Day Avg. Volume: 105,448
• 30 Day Avg. Volume: 170,880
• PEG Ratio: 0.02
• Price to Book (P/B): 1.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.50
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.15K
• Enterprise Value/Ebitda: -8.23
• 1Y Price Target: $18.60
• Price Target Upside: 25.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $13.00 ▼(-12.16% Downside)

The score is held back primarily by weak financial performance (no TTM revenue, large losses, and worsening cash burn) and a negative Phase 2 efficacy readout. These are partly offset by a supportive technical setup (above key moving averages with positive MACD) and a balance sheet with low debt and solid equity providing financial flexibility.

Positive Factors

Balance-sheet Strength

Low reported debt versus substantial equity provides durable financial flexibility, reducing near-term refinancing risk and supporting continued R&D spending. This capital structure helps sustain operations through clinical programs over the next several quarters without immediate leverage pressure.

Pipeline Advancement (PIPE-791)

Advancing PIPE-791 into a planned Phase 2 enrollment is a structural positive: it diversifies the pipeline into IPF, keeps clinical momentum, and creates a multi-year development path. This progression supports long-term value creation if the trial yields positive readouts.

Prior Demonstrated Revenue/Cash Generation

Historical 2023 revenue and profit demonstrate the business model can generate commercial revenue and positive cash flow, indicating underlying commercial capability. This precedent reduces structural execution risk if management can restore growth or monetize assets.

Negative Factors

No Recent Revenue and Large Losses

The absence of TTM revenue combined with a sizable net loss is a durable headwind, pressuring liquidity and forcing reliance on external funding. Over the next 2-6 months this reduces strategic optionality and increases execution risk for clinical programs.

Worsening Cash Burn

Rising negative operating and free cash flow signals growing funding needs and heightens dilution or financing risk. Persistently worsening cash burn limits capacity to fund multiple trials or scale operations without external capital over the medium term.

PIPE-307 Phase 2 Failure

A failed mid-stage efficacy readout materially reduces the likelihood of commercializing PIPE-307, forcing strategic reassessment. This raises long-term clinical and pipeline risk, may shift resources to other programs, and can impede partnerships or licensing opportunities.

Contineum Therapeutics, Inc. Class A Business Overview & Revenue Model

Company Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

How the Company Makes Money

Contineum Therapeutics, Inc. generates revenue through a combination of product sales, licensing agreements, and strategic collaborations. The company commercializes its proprietary therapies once they receive regulatory approval and actively engages in partnerships with other pharmaceutical companies to co-develop and co-market its drug candidates. Additionally, Contineum Therapeutics may receive milestone payments and royalties from licensing its technology and products to partners. The company's revenue model is also supported by government grants and funding from research institutions that contribute to its research and development efforts.

Contineum Therapeutics, Inc. Class A Financial Statement Overview

Summary

Overall financial profile is weak: TTM shows no revenue, a large net loss (~-$59.4M), and rising cash burn (TTM FCF ~-$52.8M vs. ~-$33.4M in 2024). The main offset is balance-sheet flexibility with low debt (~$5.5M) versus equity (~$180.5M), providing runway despite negative returns driven by losses.

Income Statement

TTM (Trailing-Twelve-Months) shows no revenue and a large net loss (about -$59.4M), indicating the business is still in heavy investment mode with limited commercial traction. Profitability has deteriorated versus 2024 (net loss widened from about -$42.3M), and recent periods are consistently loss-making. A key positive is that 2023 showed meaningful revenue ($50.0M) and positive net income ($22.7M), but that improvement has not carried into 2024–TTM, increasing earnings volatility and execution risk.

Balance Sheet

The balance sheet is currently conservatively levered: TTM debt is low (~$5.5M) relative to equity (~$180.5M), implying ample financial flexibility. Total assets remain sizable (~$190.8M) and equity is positive in the latest periods. The main weakness is performance-driven: returns on equity are negative in 2024 and TTM due to ongoing losses, and the capital structure was materially weaker in 2023 with negative equity and very high leverage, highlighting that the balance sheet quality has improved but has not been consistently stable over time.

Cash Flow

Cash generation is currently weak: TTM operating cash flow is materially negative (about -$52.5M) and free cash flow is also negative (about -$52.8M), reflecting significant cash burn. Cash burn has worsened versus 2024 (free cash flow moved from ~- $33.4M to ~- $52.8M), which raises funding/financing dependency risk. A positive offset is that cash flow is roughly in line with net losses (free cash flow to net income is near 1x in multiple periods), and 2023 demonstrated the model can generate positive operating and free cash flow, but recent trend is unfavorable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	50.00M	0.00	0.00
Gross Profit	-160.00K	-258.00K	50.00M	-329.00K	0.00
EBITDA	-61.19M	-42.00M	23.57M	-23.54M	-28.34M
Net Income	-59.39M	-42.26M	22.72M	-24.25M	-29.00M
Balance Sheet
Total Assets	190.85M	212.85M	130.39M	50.64M	70.52M
Cash, Cash Equivalents and Short-Term Investments	182.41M	204.76M	125.19M	47.24M	69.00M
Total Debt	5.49M	6.26M	193.19M	5.85M	4.91M
Total Liabilities	10.38M	14.78M	198.32M	11.37M	8.93M
Stockholders Equity	180.47M	198.07M	-67.94M	39.27M	61.59M
Cash Flow
Free Cash Flow	-52.83M	-33.36M	18.93M	-20.24M	-26.43M
Operating Cash Flow	-52.47M	-32.84M	19.35M	-20.12M	-26.27M
Investing Cash Flow	34.35M	-69.74M	-65.57M	22.30M	-64.97M
Financing Cash Flow	19.86M	109.00M	56.18M	-1.24M	79.84M

Contineum Therapeutics, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTNM, the sentiment is Positive. The current price of 14.8 is above the 20-day moving average (MA) of 12.39, above the 50-day MA of 11.83, and above the 200-day MA of 8.65, indicating a bullish trend. The MACD of 0.97 indicates Negative momentum. The RSI at 69.10 is Neutral, neither overbought nor oversold. The STOCH value of 81.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTNM.

Contineum Therapeutics, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPR	57 Neutral	$1.33B	-13.62	-107.79%	―	-52.08%	-69.35%
CTNM	54 Neutral	$540.64M	-6.56	-30.40%	―	―	-100.71%
IMRX	52 Neutral	$306.06M	-2.66	-43.75%	―	―	9.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRTS	51 Neutral	$648.01M	-14.57	-54.38%	―	―	-22.82%
ENGN	47 Neutral	$642.38M	-4.18	-53.28%	―	―	-52.86%
TVRD	46 Neutral	$36.21M	-0.39	-97.61%	―	-53.67%	86.75%

Contineum Therapeutics, Inc. Class A Corporate Events

Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan

On January 23, 2026, Contineum Therapeutics, Inc.’s board approved a new 2026 Employment Inducement Equity Incentive Plan, modeled largely on its 2024 Equity Incentive Plan but limited to non-incentive stock options and awards granted only to individuals eligible under Nasdaq rules. Adopted without stockholder approval under Nasdaq Rule 5635(c)(4), the plan initially reserves 750,000 shares of Class A common stock and is designed to grant equity awards solely to new or returning employees as a material inducement to commence employment, underscoring the company’s use of stock-based incentives to attract and retain talent in a competitive market for specialized biopharmaceutical professionals.

The most recent analyst rating on (CTNM) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.

Contineum Therapeutics Submits Phase 2 Trial for PIPE-791

On December 8, 2025, Contineum Therapeutics, Inc. Class A announced the submission of its global Phase 2 clinical trial details for PIPE-791, aimed at treating idiopathic pulmonary fibrosis (IPF), to the ClinicalTrials.gov Protocol Registration and Results System. The trial, which is expected to enroll approximately 324 subjects globally, will evaluate the safety, tolerability, and efficacy of PIPE-791 over a 26-week period. The company plans to complete the trial by June 2028, with the trial design informed by previous regulatory engagement and Phase 1 clinical trials. This initiative highlights the company’s commitment to advancing treatment options for IPF, although it faces substantial risks and uncertainties related to clinical drug development, regulatory approvals, and market competition.

The most recent analyst rating on (CTNM) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.

Contineum Therapeutics Reports Phase 2 Trial Results

On November 20, 2025, Contineum Therapeutics reported topline data from its Phase 2 VISTA trial of PIPE-307 for treating relapsing-remitting multiple sclerosis (RRMS). The trial showed that PIPE-307 had an acceptable safety and tolerability profile but did not meet its primary or secondary efficacy endpoints, as no significant change was observed in binocular 2.5% low contrast letter acuity. Despite the disappointing results, Contineum remains committed to developing therapies for inflammatory and fibrotic diseases and plans to present the complete dataset at a future medical meeting.

The most recent analyst rating on (CTNM) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.